Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

Images from 2D TIRF-SIM-TFM and aTFM microscopic methodologies.
Images from 2D TIRF-SIM-TFM and aTFM microscopic methodologies.

Two recent publications from the Biophysical Immunology Lab, led by Prof Fritzsche at the Rosalind Franklin Institute and Kennedy Institute of Rheumatology at the University of Oxford, have established novel methodologies to measure the small forces occurring in immune cells during an immune response.

The work, led by Dr. Huw Colin-York and Liliana Barbieri in Prof Marco Fritzsche's group, develops and applies new force probing methodologies by combining traction force microscopy and the unique TIRF-SIM technology established between the Fritzsche and Dustin groups in close collaboration with Prof Dong Li (Institute of Biophysics at the Chinese Academy of Science) and Prof Eric Betzig (HHMI Janelia, Noble Laureate in chemistry 2014) at the Kennedy. 

Quantifying small, rapidly evolving forces generated by cells of the immune system is a major challenge for the understanding of biomechanics and mechanobiology in health and disease. The establishment of the two force probing methods allows for measurement of small forces on the pico-Newton range at unprecedented sensitivity in 2D and 3D.

Prof Fritzsche says: "These methods offers a combination of spatio-temporal resolution enhancement relevant to forces on the nano- and sub-second scales, opening up new aspects of mechanobiology of the immune response to analysis."

The study was carried out in close collaboration with Prof Dustin at the Kennedy Institute and Prof Emad Moendarbary's group at UCL and was published in two papers in Nature Communications earlier this month.

 

Li D*, Colin-York H*, Barbieri L*, Javanmardi Y, Guo T, Korobchevskaya K, Moendarbary E, Li D, Fritzsche M, Astigmatic Traction force microscopy (aTFM)Nature Communications, 2021 (*co-first authors). 

 

Barbieri L*, Colin-York H*, Korobchevskaya K*, Li D, Karedla N, Schneider F, Dustin M, Li D, Fritzsche M, Two-dimensional TIRF-SIM Traction Force Microscopy (2D TIRF-SIM-TFM)Nature Communications, 2021 (*co-first authors). 

 

Korobchevskaya K, Colin-York H, Barbieri L, Fritzsche M, Extended mechanical force measurements using structured illumination microscopyPhilosophical Transactions Royal Society A, 2021. 

Find out more about the microscope technology

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity